Assessing Auranofin for Second‐Line Use in Chemoresistant Ovarian Cancer: Effects on Tumour Spheroid and Primary Cell Growth
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Rosamaria Militello und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Auranofin, Spheroids, Cellular. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research (MIUR), Ministero dell'Istruzione e del Merito.
Abstract (Originalsprache)
Ovarian cancer (OC) is the fifth leading cause of cancer‐related death among women and the most lethal gynaecological malignancy. The high mortality rate is primarily due to late diagnosis and the lack of targeted therapies. The gold standard treatment consists of debulking surgery followed by platinum/taxane‐based chemotherapy, which is initially effective in approximately 75% of patients. However, most women experience relapse and develop chemoresistance. To date, no therapy has proven to be decisive, underscoring the need for research into second‐line or alternative treatments to overcome chemoresistance and prevent relapses. Auranofin (AF) is a promising repositioned anticancer agent with a multifaceted mode of action both cancer cell type‐ and dose‐dependent. The current study evaluated AF's cytotoxicity on multicellular tumour spheroids derived from three ovarian cancer cell lines (SKOV3, A2780, and A2780 cisplatin‐resistant). Results demonstrated that AF inhibited spheroid formation and growth by inducing apoptosis. Furthermore, we showed that AF's mode of action involves the PI3K/Akt and NF‐κB pathways, and we highlighted differences in drug responses between cisplatin‐sensitive, resistant, and primary ovarian cancer cells. Finally, by examining the efficacy of AF and cisplatin in combination, we identified differential sensitivities among the cell lines and primary ovarian cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
- Obstetrics and Gynecology, Department of Experimental, Clinical and Biomedical Sciences 'Mario Serio', University of Florence, Careggi University Hospital, Florence, Italy.
ORCID-Profile: Francesca Magherini
Förderung
- Italian Ministry of University and Research (MIUR)
- Ministero dell'Istruzione e del Merito
Zitieren
APA
Militello, R., Becatti, M., Gamberi, T., Fiaschi, T., Modesti, A., Paffetti, C., Sorbi, F., Fambrini, M., & Magherini, F. (2025). Assessing Auranofin for Second‐Line Use in Chemoresistant Ovarian Cancer: Effects on Tumour Spheroid and Primary Cell Growth. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70681
Vancouver
Militello R, Becatti M, Gamberi T, Fiaschi T, Modesti A, Paffetti C, et al. Assessing Auranofin for Second‐Line Use in Chemoresistant Ovarian Cancer: Effects on Tumour Spheroid and Primary Cell Growth. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70681
BibTeX
@article{Militello2025,
author = {Militello, Rosamaria and Becatti, Matteo and Gamberi, Tania and Fiaschi, Tania and Modesti, Alessandra and Paffetti, Caterina and Sorbi, Flavia and Fambrini, Massimiliano and Magherini, Francesca},
title = {Assessing Auranofin for Second‐Line Use in Chemoresistant Ovarian Cancer: Effects on Tumour Spheroid and Primary Cell Growth},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70681}
}
EUVIMED